VRDN — Viridian Therapeutics, Inc.

Is VRDN overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of July 5, 2026

Viridian Therapeutics, Inc. (VRDN) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of July 5, 2026. The Healthcare name (Biotechnology) last closed at $19.40. The rating moved from Oversold to Overbought on June 18, 2026 and has changed 24 times in the last 90 days.

Public ratingOverbought (as of July 5, 2026)
Last close$19.40
Rating changesRating changed 24 times in the last 90 days
Last changeMoved from Oversold to Overbought on June 18, 2026
SectorHealthcare
IndustryBiotechnology

Latest MarketMoodz coverage

FDA Approves Lumvoa for Thyroid Eye Disease, Puts Tepezza at Risk2026-06-29

See today's live rating, score and targets

Members see the live hourly rating for VRDN — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.